



Supplementary Figure 1 | Generation and characterization of NMR-iPSCs. 
a, iPSC generation from NMR-fibroblasts. b, Culture conditions. AP activity 37 days after 
introduction of OSKM. c, Morphology of NMR-iPSCs (clones 4, 10 and 24). Scale bar, 200 µm. 
d, Telomerase activities of NMR-iPSCs. NMR-Fibro, NMR-fibroblasts; human-Fibro, human 
skin fibroblasts (TIG113); N.C., Heat-inactivated (+) samples; I.C., internal control; P.C., 
positive control. n = 3 clones. e, Proliferation of NMR-iPSCs (clones 24 and 27). f, Population 
doubling times (PDT). n = 3 clones. *P < 0.05; N.S., not significant (t-test). g, qRT-PCR 
analysis of transgene expression in NMR-iPSCs. NMR-Fibro/4F-5d, NMR-fibroblasts 5 days 
after the transduction with OSKM. Ms-iPSCs, 20D17. n = 4 clones. Results are represented as 
mean ± SD. h, RT-PCR analysis of pluripotency markers in NMR-iPSCs and NMR-fibroblasts. 
i, Immunofluorescence analysis of the expression of pluripotency markers OCT4 and 
E-cadherin. Hoechst dye (blue), nuclei. Scale bar, 100 µm. j, Principal component analysis 
(PCA) of global gene expression patterns of four NMR-iPSC clones and two NMR-fibroblast 
lines. k, RT-PCR analysis of the expression of pluripotency and differentiation markers in EBs. 
MEF2c, mesoderm; GATA4, endoderm; MAP2 and MSI1, ectoderm. U, undifferentiated; D, 




Supplementary Figure 2 | Histopathological analysis of tumours and testes after 
transplantation of iPSCs. a and b, Haematoxylin and eosin staining. Sections of tumours and 
testes of mice transplanted with NMR-iPSCs (clone 27), Ms-iPSCs (20D17) or human-iPSCs 
(201B7) (a). Scale bar, 200 µm. Testes injected with NMR-iPSCs (clone 24) 10 or 20 weeks 
after transplantation (b). Scale bar, 1 cm. c, Immunohistochemical analysis of GFP. 
Transplanted NMR-iPSCs were lentivirally labelled with GFP. Arrowhead, area of the 




Supplementary Figure 3 | Activation of ARF and frameshift mutation of ERAS in 
NMR-iPSCs. a, RT-PCR analysis of HAS2 expression in NMR-iPSCs. b, Expression of pALT. 
Results are presented as mean ± SEM. n = 3 clones. c, Western blotting of INK4a and ARF 
expression in NMR-iPSCs and NMR-fibroblasts. n = 3 clones. d, RT-PCR analysis of ERAS 
expression in NMR-iPSCs. Ms-iPSCs (20D17), positive control. ERAS com, primer-set 
designed to amplify the sequence shared by NMR-ERAS and mERas. e, Amino acid sequence 




Supplementary Figure 4 | Transforming potential of NMR-ERAS in NIH-3T3 cells. 
NIH-3T3 cells were infected with lentiviral vectors expressing NMR-ERAS or mERas. 
HRasV12, positive oncogenic control; N.C., EGFP as negative control. a, RT-PCR analysis of 
transgene expression. b, Cell morphology. Scale bar, 200 µm. c, Cell proliferation. Cells (1 × 
105) were plated on 10 cm dish and counted every other day. Data are represented as mean ± SD. 
d, Western blotting for AKT or phosphorylated-AKT expression. e, Soft agar growth assay. 
Scale bar, 200 µm. f, Tumour formation in nude mice. Cells (1 × 106) were subcutaneously 
injected and tumours were dissected 25 days later.   
 
 Supplementary Figure 5 | Characterization of NMR-iPSCs expressing mERas and/or 
shARF. a, Morphology of NMR-iPSCs (clone 24) transduced with mERas and/or shARF. Scale 
bar, 200 µm. b, qRT-PCR analysis of ARF and mERas expression in NMR-iPSCs. n = 2 clones. 
Data are represented as mean ± SEM. c, Western blotting for p21. d, The genomic sequence of 
ERas in ERas knock-out Ms-ES cell line (EGR-G101). Western blotting for AKT or 
phosphorylated-AKT expression in the indicated cell lines. Values indicate the relative intensity 
of AKT expression and phosphorylation. e, Hierarchical clustering analysis. #24, NMR-iPSC 
clone 24; #27, NMR-iPSC clone 27. f, Heat map of the selected markers of undifferentiated and 
differentiated cells. g, Selected genes shown in Supplementary Fig. 5e and f. h, Soft agar 
growth assay of NMR-iPSCs expressing mERas and/or shARF. i, Number of colonies. n = 2. 
Results are presented as mean ± SD for three experimental replicates. *P < 0.05 (one way 
ANOVA). N.S., not significant. N.C., negative control. Scale bar, 200 µm (a and g). 
 Supplementary Figure 6 | Histopathological analysis of tumours derived from NMR-iPSCs 
expressing mERas and/or shARF. a, b and c, Haematoxylin and eosin staining. Sections of 
tumours and testes 10 weeks after transplantation of NMR-iPSCs expressing mERas and/or 
shARF. Testes and tumours (a). Scale bar, 1 cm. High magnification (b). Scale bar, 200 µm. 
Representative images of teratomas formed by mERas/shARF-NMR-iPSCs (c). Scale bar, 200 
µm. d, Immunohistochemical analysis of teratomas formed by mERas/shARF-NMR-iPSCs. 
αSMA, mesoderm; VIMENTIN, mesoderm and parietal endoderm; NESTIN and GFAP, 
ectoderm. Scale bar, 200 µm. 
 Supplementary Figure 7 | Characterization of Ms-iPSCs expressing Arf. a, Morphology of 
Ms-iPSCs (20D17) expressing Arf. GFP: Nanog reporter (Nanog-GFP). Scale bar, 200 µm. b, 
qRT-PCR analysis of total Arf (endogenous and transgenic), Ink4a, Nanog and Esrrb expression 
in Arf-Ms-iPSCs. n = 3 clones (2, 3 and 4). b, bulk culture. c, Expression of the Arf transgene 
(ARF tg) in Arf-Ms-iPSC clones with (left panel) or without (right panel) hygromycin selection. 
Experimental duplicate. d, Small teratomas observed 10 weeks after transplantation of the 
High-ARF-group clone 3. Scale bar, 1 cm. e, Haematoxylin and eosin staining of a teratoma 
derived from High-ARF-group clone 3 (12 weeks) or control Ms-iPSCs (3 weeks) after 
transplantation. f, qRT-PCR analysis of Arf transgene expression in teratomas or 
undifferentiated iPSCs. Scale bar, 200 µm. Data represent the mean ± SD (b, c and f). 
  
 Supplementary Figure 8 | Differentiation potential of Arf-Ms-iPSCs. a, 
Immunocytochemical analysis of differentiated cells from the High-Arf-group clone 4. 
mesoderm (αSMA), endoderm (Albumin and Vimentin), ectoderm (Nestin and Tubb3). Scale 
bar, 200 µm. b, qRT-PCR analysis of differentiated cells from Arf-Ms-iPSCs (clone 2, 3, 4). 
pluripotent marker genes (Nanog and Esrrb) and differentiation marker genes (Des, Sox17, 
Gata6 and Sox1). U, undifferentiated; D, differentiated. Data represent the mean ± SD.  
 
Supplementary Figure 9 | ASIS as a safeguard against reprogramming and oncogenic 
transformation. a, qRT-PCR analysis of the kinetics of INK4a and ARF expression during 
reprogramming of NMR-fibroblasts. Experimental triplicate. b, qRT-PCR analysis of the 
expression of total c-MYC in NMR-iPSCs and parental NMR-fibroblasts. The primers amplified 
endogenous and transgenic c-Myc. n = 4 clones. c, RNA-seq of the levels of c-MYC target 
genes. Nineteen genes on the left, upregulated genes by c-Myc; three on the right, 
downregulated genes by c-Myc. Y-axis: expression level (FPKM) of NMR-fibroblasts relative 
to NMR-iPSCs clone 4. d, SA-βGal activity of NMR-fibroblasts expressing shARF and/or 
shINK4a and OSKM 14 days after infection. e, AP activity of NMR-fibroblasts expressing 
shARF or shINK4a and OSKM 37 days after infection. f, SA-βGal activity of NMR-fibroblasts 
expressing shARF or shINK4a and c-MYC. g, Transduction of shARF of fibroblasts with 
derepressed ARF expression induced by serial passage. SA-βGal activity 14 days after 
transduction. h, i and j, Reproducibility of the experiment of ASIS in serial passaged NMR 
fibroblasts using three independent short hairpins RNA against ARF. Cell morphology (h). Cell 
growth (i). SA-βGal-positive cells (%) (j). Data are represented as mean ± SD. *P < 0.05 (t-test). 




Supplementary Figure 10 | Expression status of senescence-associated genes in NMR 
fibroblast undergoing ASIS. 
a, Western blotting of ARF, INK4a, p21 and p53 expression in stressed NMR-fibroblasts 
expressing shARF or shINK4a. b, Western blotting of RB, AKT and MAPK (ERK and p38) 
expression in NMR fibroblast undergoing ASIS. 
  
 
 Supplementary Figure 11 | Uncropped scans of western blot results displayed in this study 
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Supplementary Table 2 | shRNA sequences 
 
